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Asthma is a very common respiratory disease which is characterized by the presence of cytokine-mediated airway
inflammation leading to smooth muscle contraction, oedema and progressive airway damage in some cases. In light
of our recent finding of an increased sero-prevalence of Helicobacter pylori in bronchiectasis, we have determined
serum levels of H. pylori-specific IgG in asthmatic and control subjects. Altogether 90 consecutive asthmatic [mean
age+SD 426+16 years and 52 female (F)] and 97 healthy control subjects (mean age+SD 432+133 years and 51
female (F); P=078 and 039 respectively) were recruited prospectively. H. pylori sero-prevalence was not
significantly dierent between asthmatic and control subjects (P4005). Serum H. pylori IgG levels did not
correlate with FEV1 % predicted, FVC % predicted or duration of asthma (P4005). Similar to the results of
previously published sero-epidemiological studies, there was a weak correlation between serum H. pylori IgG with
increasing age (r=043, P=0004). Despite the sero-epidemiological association of H. pylori infection with many
inflammatory conditions, our data showed no such association for middle age asthmatic patients with mild
intermittent asthma in our locality.
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Helicobacter pylori is a micro-aerophilic Gram-negative
spiral bacterium whose recent discovery has re-conceptua-
lized the pathogenesis and treatment of chronic active
gastritis (1,2), peptic ulcer disease (2), primary low-grade B-
cell gastric lymphoma (3) and gastric carcinoma (4). We
have recently described a high H. pylori sero-prevalence in
bronchiectasis which, similar to asthma, is a chronic
inflammatory airway disease (5). However, H. pylori sero-
prevalence in asthma has not been studied. We have,
therefore, performed this prospective study to evaluate the
H. pylori sero-prevalence in a cohort of asthmatic patients
and control subjects. In addition, we have also correlated
anti-H. pylori IgG levels with clinical disease parameters
among asthmatic patients.Received 21 July 1999 and accepted in revised form 14 February
2000.
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SUBJECT RECRUITMENT
Ninety patients with stable asthma, diagnosed according to
the American Thoracic Society Guidelines, were recruited
from the outpatient clinics of the University of Hong Kong
between December 1997 and December 1998 (6). Briefly,
asthma was diagnosed as ‘a presence of widespread
narrowing of airways, which manifested clinically as
alteration of dyspnoea and other respiratory symptoms,
with or without accompanied changes in lung function
indices. This airway narrowing typically altered in severity
and was characterized by increased responsiveness of the
trachea and bronchi to various stimuli.’ ‘Stable asthma’ was
defined as ‘the presence of no significant changes in
respiratory symptoms or signs for three consecutive weeks’.
None of these patients had known peptic ulcer disease,
bronchiectasis or other respiratory diseases. Blood was also
collected from healthy subjects who attended health
exhibitions designed for public health education. These
subjects had no known history of peptic ulcer, cerebrovas-
cular, ischaemic heart or respiratory diseases. None of the
control subjects had ever smoked. Written consent was
obtained from each patient for venesection and lung
function testing, and these procedures were approved by
the institutional ethics committee.# 2000 HARCOURT PUBLISHERS LTD
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The following data were collected from the asthma patients:
age, gender, spirometry, i.e. forced expiratory volume in 1
sec (FEV1) and forced vital capacity (FVC) (expressed as
percent predicted), number of years since the diagnosis of
asthma was made by a qualified physician, smoking history,
history of known ischaemic heart disease and proven peptic
ulcer, other medical conditions and current medications.
Serum obtained from both groups of subjects were assayed
for the level and sero-status (positive, negative or equivo-
cal) of H. pylori-specific IgG. All the subjects were
occupationally classified according to the British Registrar
General, as classes 1, 2, 3, 4 and 5 for professional,
intermediate, skilled manual, partly skilled manual and
unskilled manual workers respectively.
DETERMINATION OF H. PYLORI-SPECIFIC
IGG USING ENZYME-LINKED
IMMUNOSORBENT ASSAY (ELISA)
The detailed methodology has been described elsewhere
(5,7). Briefly, 100ml of IgG calibrator, control and diluted
serum from patient or control groups (stored at 7708C
before use) were pipetted into the microtitre wells (coated
with purified H. pylori group specific antigens) of a
commercially available ELISA kit (Bio-Rad, Hercules,
USA) and discarded after incubation for 60 min at 258C.
Washing of the wells was followed by addition of 100 ml of
anti-IgG enzyme conjugate and incubation with the work-
ing solution. The optical density and therefore H. pylori-
specific IgG were determined spectrometrically at 450 nm
for each specimen. A positive, equivocal and negative result
for IgG against H. pylori was assigned when the concentra-
tion was greater than 20, between 125 and 20, and less than
125U71ml, respectively. The sensitivity and specificity ofTABLE 1. Clinical and Helicobacter pylori serological parameter
Parameters Controls
(n=97)
All patients
(n=90)
Age (years) 432133 42616
Female gender (%) 526 578
Forced expiratory volume in 1 sec
(% predicted)
— 810279
Forced vital capacity (% predicted) — 960236
Duration of asthma (years) — 173116
H. pylori IgG level (unit71ml) 240214 248191
H. pylori IgG sero-positivity (%) 381 473
Data shown are mean  SD.* and { are P-values for comparing
H. pylori IgG positive and negative patients respectively.this ELISA kit in our patient population are 95 and 85%
respectively (5).
STATISTICAL ANALYSIS
Data were compared between groups using unpaired
Student’s t-test and presented as mean  SD. The relation-
ship between variables were examined using conventional
Pearson’s correlation analysis. The analysis was performed
in the SAS software. A P-value of less than 005 was taken
as statistically significant (7).
Results
SUBJECT DEMOGRAPHY AND CLINICAL
DETAILS
Altogether 90 consecutive asthmatic and 97 control subjects
were recruited into this study. The demographic and clinical
details of these subjects are shown in Table 1. There was no
significant dierence in age or gender between the study
and control groups (P4005). In addition, there was no
significant dierence in the occupational social class
between the asthmatic and control subjects (32+12,
33612, P=067). There were 15 current and three ex-
smokers amongst the asthmatic subjects. Within the
asthmatic group of patients, a history of rhinitis (n=32),
active (n=1) and previously treated (n=4) tuberculosis,
hypertension (n=4), eczema (n=4), treated hypothyroid-
ism (n=1) or hyperthyroidism (n=3), cirrhosis due to
chronic hepatitis (n=3), osteoarthritis (n=2), uterine
fibroids (n=2), bronchial carcinoma (n=1), colonic carci-
noma (n=1) and osteoporosis (n=1) was elicited. Medica-
tions taken by the asthma patients included inhaled
bronchodilators (n=90), inhaled corticosteroids (n=68),
theophylline (n=29), nasal inhaled corticosteroids (n=17),s in asthma patients and control subjects
Asthma patients *P-value *P-value
H. pylori IgG
positive (n=44)
H. pylori IgG
negative (n=46)
453165 40153 078 012
636 522 039 038
793243 825308 — 059
917211 99625 — 009
175131 171101 — 087
385169 10465 079 500001
489 511 030 099
data between controls and all asthmatic patients, and between
758 K. W. TSANG ET AL.oral b2-agonists (n=11), oral calcium supplement (n=7),
thiazide diuretics for hypertension (n=4), oral maintenance
prednisolone (n=2), rifampicin and isoniazid (n=1), and
thyroxine (n=1).
H. PYLORI-SPECIFIC IGG
The serological parameters are shown in Table 1. There
were no significant dierences in the H. pylori-specific IgG
levels between the control and study groups (P4005).
Amongst the asthmatic patients, H. pylori sero-positive
individuals did not dier significantly from their sero-
negative counterparts in age, gender, FEV1 % predicted,
FVC % predicted or duration of asthma (Table 1,
P4005). However, there was a correlation between age
and H. pylori-specific IgG level (r=043, P=0004)
amongst the asthmatic patients. There was no significant
correlation (data not shown) between H. pylori-specific IgG
with gender (P=042), FEV1 % predicted (P=031), FVC
% predicted (P=019) or number of years since diagnosis
of asthma (P=030).
Discussion
The results of this study show that patients with asthma did
not have a significant dierence in H. pylori sero-prevalance
from control subjects, who had similar age, gender
distribution and occupational social class. In addition,
serum H. pylori IgG levels did not correlate with FEV1 %
predicted, FVC % predicted or duration of asthma
(P4005). Similar to the results of previously published
sero-epidemiological studies, we found a correlation
between serum H. pylori IgG with increasing age. Despite
the sero-epidemiological association of H. pylori infection
with many inflammatory conditions (5,8–11), our data
showed no such association among middle age patients
with mild intermittent asthma in our locality.
H. pylori infection, often totally asymptomatic, is a
worldwide problem which particularly aects subjects with
increasing age, lower socio-economic status, residence in
less developed countries, and clustering living environment
(12–14). Increased H. pylori sero-prevalence has also been
reported in many extradigestive disorders including ischae-
mic heart disease (15), stroke (15), and particularly chronic
inflammatory diseases such as rosacea, urticaria and
Henoch–Schonlein purpura (8–11). Interestingly, the latter
three conditions have been reported to improve after
eradication of H. pylori (8–11). In addition to an increased
H. pylori sero-positivity amongst patients with atrophic
thyroditis, there is also a correlation between microsomal
IgG level, which reflects disease activity in thyroiditis, and
anti-H. pylori IgG level (11).
We have recently reported a high incidence of H. pylori
sero-positivity in patients who suer from bronchiectasis
(76%) compared with healthy subjects (543%, P=0001)
even after adjustment for age, social class and household
crowdedness (5). H. pylori IgG level also correlated with
24h sputum volume, which is a strong surrogate marker for
disease activity in bronchiectasis (5). The potential role ofH. pylori infection in the pathogenesis of bronchiectasis and
the aforementioned conditions are unknown although it is
possible that H. pylori might play a pro-inflammatory role
and co-trigger these diseases with other more specific
environmental, genetic and unknown factors (16).
Although bronchiectasis and asthma could have very
dierent aetiology and clinical features, similarities in the
pathogenesis of the two diseases occur at the cellular and
biochemical levels. For instance, both of these inflamma-
tory airway diseases employ similar profiles of pro-
inflammatory mediators including leukotriene B4, inter-
leukin (IL)-1b, tumour necrosis factor and IL-8 (71–19).
These mediators promote tracking of neutrophils and
other leukocytes into the airways leading to further
mucosal damage and epithelial remodelling. (71–19).
Inhaled corticosteroids are capable of improving these
inflammatory activities and down-regulate pro-inflamma-
tory cytokine production in both conditions. (20–22).
Histologically similar mucosal swelling and desquamation
of damaged epithelial cells also occur in bronchiectasis and
asthma (23,24). The above observations in asthma and
bronchiectasis have also been reported inH. pylori infection
of gastric mucosa. Inflammation plays a very prominent
role in H. pylori infection of gastric mucosa, which
manifests as intense submucosal infiltration by neutrophils
and monocytes (25). This intense gastric mucosal inflam-
mation is also mediated by the aforementioned pro-
inflammatory mediators, and is probably initiated by the
production of H. pylori enzymes such as urease, catalase,
proteases, lipases, and phospholipases (26–28).
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